ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs

Bibliography

• JENNETTE JC, WILKMAN AS, FALK RJ: Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am. J. Pathol. (1989) 135:921-930.
   PubMed Web of Science ®Google Scholar
• JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides: the proposal of an International Consensus Conference. Arthritis Rheum. (1994) 37:187-192.
   PubMed Web of Science ®Google Scholar
• WATTS RA, LANE S, SCOTT DG: What is known about the epidemiology of the vasculitides? Best Pract. Res. Clin. Rheumatol. (2005) 19(2):191-207.
   PubMed Web of Science ®Google Scholar
• HARPER L, SAVAGE CO: ANCA-associated renal vasculitis at the end of the twentieth century – a disease of older patients. Rheumatology (Oxf.) (2005) 44(4):495-501.
   PubMed Web of Science ®Google Scholar
• BOOTH AD, ALMOND MK, BURNS A et al.: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. (2003) 41(4):776-784.
   PubMed Web of Science ®Google Scholar
• FALK RJ, HOGAN S, CAREY TS, JENNETTE JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann. Int. Med. (1990) 113:656-663.
   PubMed Web of Science ®Google Scholar
• HOGAN S, NACHMAN P, WILKMAN A, JENNETTE J, FALK R: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-assocaited microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. (1996) 7(1):23-32.
   PubMed Web of Science ®Google Scholar
• HAUER HA, BAJEMA IM, VAN HOUWELINGEN HC et al.: Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. (2002) 62(5):1732-1742.
   PubMed Web of Science ®Google Scholar
• BANSAL PJ, TOBIN MC: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol. (2004) 93(4):398-401.
   PubMed Web of Science ®Google Scholar
• CHOI HK, SLOT MC, PAN G, WEISSBACH CA, NILES JL, MERKEL PA: Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum. (2000) 43(11):2488-2492.
   PubMed Web of Science ®Google Scholar
• COHEN TERVAERT J, POPA E, BOS N: The role of superantigens in vasculitis. Curr. Opin. Rheum. (1999) 11:24-33.
   PubMedGoogle Scholar
• LANE SE, WATTS RA, BENTHAM G, INNES NJ, SCOTT DG: Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. (2003) 48(3):814-823.
   PubMed Web of Science ®Google Scholar
• HAGEN E, DAHA M, HERMANS J et al.: Diagnostic value of standardised assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. (1998) 53:743-753.
   PubMed Web of Science ®Google Scholar
• BOOMSMA MM, STEGEMAN CA, VAN DER LEIJ MJ et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. (2000) 43(9):2025-2033.
   PubMed Web of Science ®Google Scholar
• XIAO H, HEERINGA P, HU P et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. (2002) 110(7):955-963.
   PubMed Web of Science ®Google Scholar
• LITTLE MA, SMYTH CL, YADAV R et al.: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte–microvascular interactions in vivo. Blood (2005) 106(6):2050-2058.
   PubMed Web of Science ®Google Scholar
• PFISTER H, OLLERT M, FROHLICH LF et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood (2004) 104(5):1411-1418.
   PubMed Web of Science ®Google Scholar
• TRAVIS WD, HOFFMAN GS, LEAVITT RY, PASS HI, FAUCI AS: Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am. J. Surg. Pathol. (1991) 15(4):315-333.
   PubMed Web of Science ®Google Scholar
• COCKWELL P, BROOKS C, ADU D, SAVAGE C: Interleukin-8: a pathogenetic role in antineutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis. Kidney Int. (1999) 55:852-863.
   PubMed Web of Science ®Google Scholar
• XIAO H, HEERINGA P, LIU Z et al.: The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am. J. Pathol. (2005) 167(1):39-45.
   PubMed Web of Science ®Google Scholar
• HARPER L, COCKWELL P, ADU D, SAVAGE C: Neutrophil priming and apoptosis in ANCA-associated vasculitis. Kidney Int. (2001) 59:1729-1738.
   PubMed Web of Science ®Google Scholar
• MULLER KUBOLD A, MESANDER G, STEGEMAN C, KALLENBERG C, COHEN TERVAERT J: Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides? Clin. Exp. Immunol. (1998) 114:491-499.
   PubMed Web of Science ®Google Scholar
• FALK RJ, TERRELL RS, CHARLES LA, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. USA (1990) 87:4115-4119.
   PubMed Web of Science ®Google Scholar
• ZHOU Z, RICHARD C, MENARD HA: De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells. J. Rheumatol. (2000) 27(10):2406-2411.
   PubMed Web of Science ®Google Scholar
• CONDLIFFE AM, CHILVERS ER, HASLETT C, DRANSFIELD I: Priming differentially regulates neutrophil adhesion molecule expression/function. Immunology (1996) 89:105-111.
   PubMed Web of Science ®Google Scholar
• MCLEISH KR, KLEIN JB, LEDERER ED, HEAD KZ, WARD RA: Azotemia, TNF-α, and LPS prime the human neutrophil oxidative burst by distinct mechanisms. Kidney Int. (1996) 50:407-416.
   PubMed Web of Science ®Google Scholar
• DEWAS C, DANG PM, GOUGEROT-POCIDALO MA, EL-BENNA J: TNF-α induces phosphorylation of p47(phox) in human neutrophils: partial phosphorylation of p47phox is a common event of priming of human neutrophils by TNF-α and granulocyte-macrophage colony-stimulating factor. J. Immunol. (2003) 171(8):4392-4398.
   PubMed Web of Science ®Google Scholar
• KETTRITZ R, SCHREIBER A, LUFT FC, HALLER H: Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. (2001) 12(1):37-46.
   PubMed Web of Science ®Google Scholar
• YUO A, KITAGAWA S, KASAHARA T, MATSUSHIMA K, SAITO M, TAKAKU F: Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood (1991) 78(10):2708-2714.
   PubMed Web of Science ®Google Scholar
• HUUGEN D, XIAO H, VAN ESCH A et al.: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-α. Am. J. Pathol. (2005) 167(1):47-58.
   PubMed Web of Science ®Google Scholar
• LITTLE MA, BHANGAL G, SMYTH CL et al.: Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. (2006) 17(1):160-169.
   PubMed Web of Science ®Google Scholar
• HEWINS P, MORGAN M, WILLIAMS JM, SAVAGE CO, HARPER L: IL-18 is up-regulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. Kidney Int. (2006) 69:605-615.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JM, BEN-SMITH A, HEWINS P et al.: Activation of the Gi heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J. Am. Soc. Nephrol. (2003) 14(3):661-669.
   PubMed Web of Science ®Google Scholar
• HEWINS P, WILLIAMS JM, WAKELAM MJ, SAVAGE CO: Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcγ receptors and CD18. J. Am. Soc. Nephrol. (2004) 15(3):796-808.
   PubMed Web of Science ®Google Scholar
• RADFORD D, LORD J, SAVAGE C: The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation. Clin. Exp. Immunol. (1999) 118:171-179.
   PubMed Web of Science ®Google Scholar
• BEN-SMITH A, DOVE S, MARTIN A, WAKELAM M, SAVAGE C: Anti-neutrophil cytoplasmic autoantibodies from patients with systemic vasculitis activate neutrophils via distinct signalling cascades compared to conventional Fcγ receptor ligation. Blood (2001) 981:1448-1455.
   Google Scholar
• WILLIAMS JM, SAVAGE CO: Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J. Am. Soc. Nephrol. (2005) 16(1):90-96.
   PubMed Web of Science ®Google Scholar
• REUMAUX D, KUIJPERS TW, HORDIJK PL, DUTHILLEUL P, ROOS D: Involvement of Fcγ receptors and β2 integrins in neutrophil activation by anti-proteinase-3 or anti-myeloperoxidase antibodies. Clin. Exp. Immunol. (2003) 134(2):344-350.
   PubMed Web of Science ®Google Scholar
• SAVAGE CO, HARPER L, HOLLAND M: New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr. Opin. Rheumatol. (2002) 14(1):15-22.
   PubMed Web of Science ®Google Scholar
• CALDERWOOD JW, WILLIAMS JM, MORGAN MD, NASH GB, SAVAGE CO: ANCA induces β2 integrin and CXC chemokine-dependent neutrophil–endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J. Leukoc. Biol. (2004) 30:30.
   Google Scholar
• HARPER L, REN Y, SAVILL J, ADU D, SAVAGE C: Dysregulated neutrophil apoptosis in systemic vasculitis. Am. J. Pathol. (2000) 157:211-220.
   PubMed Web of Science ®Google Scholar
• DAY CJ, HEWINS P, SAVAGE CO: New developments in the pathogenesis of ANCA-associated vasculitis. Clin. Exp. Rheumatol. (2003) 21(6 Suppl. 32):S35-S48.
   PubMed Web of Science ®Google Scholar
• LAMPRECHT P, OFF BALANCE: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin. Exp. Immunol. (2005) 141(2):201-210.
   PubMed Web of Science ®Google Scholar
• GISCOMBE R, WANG XB, KAKOULIDOU M, LEFVERT AK: Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J. Int. Med. (2006) 260(3):224-230.
   PubMed Web of Science ®Google Scholar
• MARINAKI S, NEUMANN I, KALSCH AI et al.: Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin. Exp. Immunol. (2005) 140(1):181-191.
   PubMed Web of Science ®Google Scholar
• POPA ER, STEGEMAN CA, BOS NA, KALLENBERG CG, TERVAERT JW: Differential B- and T-cell activation in Wegener's granulomatosis. J. Allergy Clin. Immunol. (1999) 103(5 Part 1):885-894.
   PubMed Web of Science ®Google Scholar
• PENDERGRAFT WF III, PRESTON GA, SHAH RR et al.: Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat. Med. (2004) 10(1):72-79.
   PubMed Web of Science ®Google Scholar
• FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Int. Med. (1983) 98:76-85.
   PubMed Web of Science ®Google Scholar
• HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener's granulomatosis: an analysis of 158 patients. Ann. Int. Med. (1992) 116:488-498.
   PubMed Web of Science ®Google Scholar
• DE GROOT K, ADU D, SAVAGE C: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. (2001) 16:2018-2027.
   PubMed Web of Science ®Google Scholar
• PUSEY CD, REES AJ, EVANS DJ, PETERS DK, LOCKWOOD CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. (1991) 40(4):757-763.
   PubMed Web of Science ®Google Scholar
• JAYNE DRW, GASKIN G, RASMUSSEN N et al.: Randomised trial of plasma exchange versus methyl prednisolone for severe renal vasculitis. N. Engl. J. Med. (2006) (In Press).
   Google Scholar
• KLEMMER PJ, CHALERMSKULRAT W, REIF MS, HOGAN SL, HENKE DC, FALK RJ: Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am. J. Kidney Dis. (2003) 42(6):1149-1153.
   PubMed Web of Science ®Google Scholar
• THOMAS-GOLBANOV C, SRIDHARAN S: Novel therapies in vasculitis. Expert Opin. Investig. Drugs (2001) 10(7):1279-1289.
   PubMed Web of Science ®Google Scholar
• DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. (2005) 52(8):2461-2469.
   PubMed Web of Science ®Google Scholar
• JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. (2003) 349(1):36-44.
   PubMed Web of Science ®Google Scholar
• SLOT MC, TERVAERT JW, BOOMSMA MM, STEGEMAN CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. (2004) 51(2):269-273.
   PubMed Web of Science ®Google Scholar
• ALLISON AC, EUGUI EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 47(2-3):85-118.
   PubMed Web of Science ®Google Scholar
• DOOLEY MA: Mycophenylate mofetil: what role in the treatment of lupus? Lupus (2006) 15(3):179-182.
   PubMed Web of Science ®Google Scholar
• LAU CH, COMER M, LIGHTMAN S: Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin. Exp. Ophthalmol. (2003) 31(6):487-491.
   PubMed Web of Science ®Google Scholar
• NOWACK R, GOBEL U, KLOOKER P, HERGESALL O, ANDRASSY K, VAN DER WOUDE F: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study of 11 patients with renal involvement. J. Am. Soc. Nephrol. (1999) 10:1965-1971.
   PubMed Web of Science ®Google Scholar
• LANGFORD CA, TALAR-WILLIAMS C, SNELLER MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. (2004) 51(2):278-283.
   PubMed Web of Science ®Google Scholar
• STEGEMAN CA, COHEN-TERVAERT JW: Mycophenolate mofetil for remission induction in patients with active Wegener’s granulomatosis intolerant of cyclophosphamide. J. Am. Soc. Nephrol. (2000) 11:98A.
   Google Scholar
• JOY MS, HOGAN SL, JENNETTE JC, FALK RJ, NACHMAN PH: A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant. (2005) 20(12):2725-2732.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, TARANTINO A: Promising new agents in the prevention of transplant rejection. Drugs RD (1999) 1(1):55-60.
   PubMedGoogle Scholar
• BIRCK R, WARNATZ K, LORENZ H et al.: 15-Deoxyspergualin for refractory Wegenr's granulomatosis and microscopic polyangiitis: results of a multicentre trial. J. Am. Soc. Nephrol. (2001) 12:191A.
   Google Scholar
• SCHMITT WH, BIRCK R, HEINZEL PA et al.: Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol. Dial. Transplant. (2005) 20(6):1083-1092.
   PubMed Web of Science ®Google Scholar
• METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxf.) (2004) 43(3):315-320.
   PubMed Web of Science ®Google Scholar
• NORONHA IL, KRUGER C, ANDRASSY K, RITZ E, WALDHERR R: In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. (1993) 43:682-692.
   PubMed Web of Science ®Google Scholar
• TESAR V, MASEK Z, RYCHLIK I et al.: Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol. Dial. Transplant. (1998) 13(7):1662-1667.
   PubMed Web of Science ®Google Scholar
• KINDLER V, SAPPINO AP, GRAU GE, PIGUET PF, VASSALLI P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 56(5):731-740.
   PubMed Web of Science ®Google Scholar
• BOOTH A, HARPER L, HAMMAD T et al.: Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. (2004) 15(3):717-721.
   PubMed Web of Science ®Google Scholar
• STONE J, UHLFELDER M, HELLMANN D, CROOK S, BEDOCS N, HOFFMAN G: Etanercept combined with conventional treatment in Wegener's granulomatosis. Arthritis Rheum. (2001) 44:1149-1154.
   PubMed Web of Science ®Google Scholar
• WEGENER'S GRANULOMATOSISETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. (2005) 352(4):351-361.
   PubMed Web of Science ®Google Scholar
• STONE JH, HOLBROOK JT, MARRIOTT MA et al.: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. (2006) 54(5):1608-1618.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep. (2003) 5(6):501-505.
   PubMedGoogle Scholar
• SCALLON B, CAI A, SOLOWSKI N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. (2002) 301(2):418-426.
   PubMed Web of Science ®Google Scholar
• VOSWINKEL J, MUELLER A, KRAEMER JA et al.: B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. (2006) 65(7):859-864.
   PubMed Web of Science ®Google Scholar
• KRUMBHOLZ M, SPECKS U, WICK M, KALLED SL, JENNE D, MEINL E: BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. (2005) 25(4):298-302.
   PubMed Web of Science ®Google Scholar
• CHAMBERS SA, ISENBERG D: Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus (2005) 14(3):210-214.
   PubMed Web of Science ®Google Scholar
• KEOGH KA, YTTERBERG SR, FERVENZA FC, CARLSON KA, SCHROEDER DR, SPECKS U: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. (2005) 173(2):180-187.
   PubMed Web of Science ®Google Scholar
• ARIES PM, HELLMICH B, VOSWINKEL J et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. (2006) 65(7):853-858.
   PubMed Web of Science ®Google Scholar
• TIPPING PG, HOLDSWORTH SR: T cells in crescentic glomerulonephritis. J. Am. Soc. Nephrol. (2006) 17(5):1253-1263.
   PubMed Web of Science ®Google Scholar
• SZPIRIT W, RASMUSSEN N, PEDERSON J: Plasma exchange and cyclosporin A in Wegener's granulomatosis: a controlled study. Int. J. Artif. Organs (1996) 10:51-54.
   Google Scholar
• HAUBITZ M, KOCH KM, BRUNKHORST R: Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol. Dial. Transplant. (1998) 13(8):2074-2076.
   PubMed Web of Science ®Google Scholar
• SCHMITT WH, HAGEN EC, NEUMANN I, NOWACK R, FLORES-SUAREZ LF, VAN DER WOUDE FJ: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. (2004) 65(4):1440-1448.
   PubMed Web of Science ®Google Scholar
• LOCKWOOD C, THIRU S, STEWART S et al.: Treatment of refractory Wegener's granulomatosis with humanised monoclonal antibodies. QJ Med. (1996) 89:903-912.
   Google Scholar
• SANSOM DM, WALKER LS: The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev. (2006) 212:131-148.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, GREENE JL, BRADY W, BAJORATH J, LEDBETTER JA, PEACH R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 1(9):793-801.
   PubMed Web of Science ®Google Scholar
• GREENE JL, LEYTZE GM, EMSWILER J et al.: Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. (1996) 271(43):26762-26771.
   PubMed Web of Science ®Google Scholar
• KREMER JM, DOUGADOS M, EMERY P et al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2005) 52(8):2263-2271.
   PubMed Web of Science ®Google Scholar
• ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. (1999) 103(9):1243-1252.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, LARSEN C, DURRBACH A et al.: Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. (2005) 353(8):770-781.
   PubMed Web of Science ®Google Scholar
• REYNOLDS J, TAM FW, CHANDRAKER A et al.: CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. (2000) 105(5):643-651.
   PubMed Web of Science ®Google Scholar
• GROHMANN U, ORABONA C, FALLARINO F et al.: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. (2002) 3(11):1097-1101.
   PubMed Web of Science ®Google Scholar
• UEDA H, HOWSON JM, ESPOSITO L et al.: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 423:506-511.
   PubMed Web of Science ®Google Scholar
• ZHOU Y, HUANG D, PARIS PL, SAUTER CS, PROCK KA, HOFFMAN GS: An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum. (2004) 50(8):2645-2650.
   PubMed Web of Science ®Google Scholar
• STEEBER DA, VENTURI GM, TEDDER TF: A new twist to the leukocyte adhesion cascade: intimate cooperation is key. Trends Immunol. (2005) 26(1):9-12.
   PubMed Web of Science ®Google Scholar
• SALMELA K, WRAMNER L, EKBERG H et al.: A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation (1999) 67(5):729-736.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37(7):992-999.
   PubMed Web of Science ®Google Scholar
• PALL AA, HOWIE AJ, ADU D et al.: Glomerular vascular cell adhesion molecule-1 expression in renal vasculitis. J. Clin. Pathol. (1996) 49:238-242.
   PubMed Web of Science ®Google Scholar
• VUORTE J, LINDSBERG PJ, KASTE M et al.: Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J. Immunol. (1999) 162(4):2353-2357.
   PubMed Web of Science ®Google Scholar
• FORBESS JM, HIRAMATSU T, NOMURA F et al.: Anti-CD11b monoclonal antibody improves myocardial function after six hours of hypothermic storage. Ann. Thorac. Surg. (1995) 60(5):1238-1244.
   PubMed Web of Science ®Google Scholar
• ANDERSON ME, SIAHAAN TJ: Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides (2003) 24(3):487-501.
   PubMed Web of Science ®Google Scholar
• YUSUF-MAKAGIANSAR H, ANDERSON ME, YAKOVLEVA TV, MURRAY JS, SIAHAAN TJ: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. (2002) 22(2):146-167.
   PubMed Web of Science ®Google Scholar
• ARNAUD C, BRAUNERSREUTHER V, MACH F: Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc. Med. (2005) 15(6):202-206.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7(6):687-692.
   PubMed Web of Science ®Google Scholar
• CHOI M, ROLLE S, RANE M, HALLER H, LUFT FC, KETTRITZ R: Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. (2003) 63(1):96-106.
   PubMedGoogle Scholar
• AIELLO LP, CLERMONT A, ARORA V, DAVIS MD, SHEETZ MJ, BURSELL SE: Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci. (2006) 47(1):86-92.
   PubMed Web of Science ®Google Scholar
• NONAKA A, KIRYU J, TSUJIKAWA A et al.: PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci. (2000) 41(9):2702-2706.
   PubMed Web of Science ®Google Scholar
• KARUSSIS D, ABRAMSKY O, GRIGORIADIS N et al.: The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. (2001) 120(1-2):1-9.
   PubMed Web of Science ®Google Scholar
• CLARKE HC, KOCHER HM, KHWAJA A, KLOOG Y, COOK HT, HENDRY BM: Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J. Am. Soc. Nephrol. (2003) 14(4):848-854.
   PubMed Web of Science ®Google Scholar
• EVANS CH, GOUZE E, GOUZE JN, ROBBINS PD, GHIVIZZANI SC: Gene therapeutic approaches – transfer in vivo. Adv. Drug Deliv. Rev. (2006) 58(2):243-258.
   PubMed Web of Science ®Google Scholar
• IMAI E, TAKABATAKE Y, MIZUI M, ISAKA Y: Gene therapy in renal diseases. Kidney Int. (2004) 65(5):1551-1555.
   PubMed Web of Science ®Google Scholar
• YOKOO T, OHASHI T, UTSUNOMIYA Y et al.: Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome. Blood (2001) 98(1):57-64.
   PubMed Web of Science ®Google Scholar
• TOMITA N, MORISHITA R, LAN HY et al.: In vivo administration of a nuclear transcription factor-κB decoy suppresses experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. (2000) 11(7):1244-1252.
   PubMed Web of Science ®Google Scholar
• CAO CC, DING XQ, OU ZL et al.: In vivo transfection of NF-κB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int. (2004) 65(3):834-845.
   PubMed Web of Science ®Google Scholar
• LITTLE MH: Regrow or repair: potential regenerative therapies for the kidney. J. Am. Soc. Nephrol. (2006) 17(9):2390-2401.
   PubMed Web of Science ®Google Scholar
• MARINAKI AM, ANSARI A, DULEY JA et al.: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics (2004) 14(3):181-187.
   PubMedGoogle Scholar
• TAKADA K, AREFAYENE M, DESTA Z et al.: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. (2004) 50(7):2202-2210.
   PubMed Web of Science ®Google Scholar